Novartis CEO Vas Narasimhan said he was pleased with the performance of established medicines as well as new drug launches, contributing to the company's positive momentum.

The CEO also noted the geographically diverse performance, with significant achievements in the US, Europe, China and Japan. Despite some delays, Narasimhan reaffirmed Novartis' commitment to achieving more than 5% sales growth by 2028 and a margin in excess of 40% by 2027, driven by better-than-expected sales of heart disease and psoriasis medicines.

Particular focus was placed on the cancer drug Pluvicto, underlining solid quarter-on-quarter growth and confidence in its potential despite a slight delay compared to expectations. 

Bloomberg TV provided by MT Newswires

Bloomberg videos